CompletedPhase 2NCT03251443

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking Union Medical College Hospital
Principal Investigator
Hai-tao Zhao
Peking Union Medical College Hospital (PUMCH)
Intervention
Apatinib(drug)
Enrollment
34 target
Eligibility
18 years · All sexes
Timeline
20172019

Study locations (1)

Collaborators

Jiangsu HengRui Medicine Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03251443 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials